End stage renal desease patients who underwent hemodialysis treatment. Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: Intervention: Pentoxifylline: PTX tablet (400 mg) orally once a day. Intervention 2: Control: One starch tablet once a
day.
Treatment - Drugs
Placebo
Intervention: Pentoxifylline: PTX tablet (400 mg) orally once a day
Control: One starch tablet once a
day
Sponsors
Zahedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Arteriovenous fistula as vascular access, Hemodialysis patients at least 2 months prior trial. Exclusion criteria: Chronic active liver disease, Any infectious disease 2 months before the study, Failed kidney graft, Hypersensitivity to PTX or other methylxanthines, Hemorrhage/clotting disorders, Risk for worsening pre-existing cardiac arrhythmias or arterial hypotension, Treatment with antibiotics, non-steroidal anti-inflammatory drugs, steroids, immunosuppressives, statins or PTX 3 months previous to the study
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum CRP concentrations. Timepoint: At 0, 2 and 4 months of intervention. Method of measurement: Serum CRP concentrations. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Ali Alidadi
Zahedan University of Medical Sciences
Outcome results
None listed